Arch Oncology Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Out of Business

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Out of Business

Arch Oncology General Information

Description

Developer of second-generation antibodies designed for the treatment of solid tumors. The company's antibodies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer and it not only acts as an immune checkpoint inhibitor but also selectively kills tumor cells, enabling patients to get options to treat cancer.

Contact Information

Website
www.archoncology.com
Formerly Known As
Vasculox, Tioma Therapeutics
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2000 Sierra Point Parkway
  • Suite 700
  • Brisbane, CA 94005
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2000 Sierra Point Parkway
  • Suite 700
  • Brisbane, CA 94005
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arch Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Out of Business 31-May-2024 Completed Out of Business
12. Later Stage VC (Series C) 27-Apr-2021 Completed Clinical Trials - Phase 1
11. Later Stage VC (Series B) 11-Mar-2021 Completed Clinical Trials - Phase 1
10. Debt - PPP 29-Apr-2020 Completed Clinical Trials - Phase 1
9. Later Stage VC (Series B) 25-Mar-2019 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series A1) 04-Feb-2018 Completed Pre-Clinical Trials
7. Later Stage VC (Series A) 04-Aug-2016 Completed Pre-Clinical Trials
6. Grant 29-Sep-2013 Completed Pre-Clinical Trials
5. Grant 01-May-2013 $827K Completed Pre-Clinical Trials
4. Grant 01-May-2012 $707K Completed Pre-Clinical Trials
To view Arch Oncology’s complete valuation and funding history, request access »

Arch Oncology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A1 15,393,186 $0.001000 $0.06 $0.69 $0.69 1x $0.69 8.22%
To view Arch Oncology’s complete cap table history, request access »

Arch Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of second-generation antibodies designed for the treatment of solid tumors. The company's antibodies represent
Drug Discovery
Brisbane, CA
10 As of 2023

Haddonfield, NJ
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arch Oncology Competitors (2)

One of Arch Oncology’s 2 competitors is Linnaeus Therapeutics, a Venture Capital-Backed company based in Haddonfield, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Linnaeus Therapeutics Venture Capital-Backed Haddonfield, NJ
IgGenix Venture Capital-Backed South San Francisco, CA
You’re viewing 2 of 2 competitors. Get the full list »

Arch Oncology Patents

  • 68

    Total Documents Applications and Grants

  • Total Patents Families

  • 20

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Arch Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021264006-A1 Therapeutic sirpalpha antibodies Inactive 30-Apr-2020
US-20230279108-A1 Therapeutic sirp-alpha antibodies Inactive 30-Apr-2020
JP-2023524238-A Therapeutic sirpα antibodies Inactive 30-Apr-2020
AU-2020372327-A1 Combination therapy for the treatment of solid and hematological cancers Inactive 23-Oct-2019
US-20220313819-A1 Combination therapy for the treatment of solid and hematological cancers Inactive 23-Oct-2019 A61K39/3955
To view Arch Oncology’s complete patent history, request access »

Arch Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Arch Oncology FAQs

  • When was Arch Oncology founded?

    Arch Oncology was founded in 2006.

  • Where is Arch Oncology headquartered?

    Arch Oncology is headquartered in Brisbane, CA.

  • What is the size of Arch Oncology?

    Arch Oncology has 10 total employees.

  • What industry is Arch Oncology in?

    Arch Oncology’s primary industry is Drug Discovery.

  • Is Arch Oncology a private or public company?

    Arch Oncology is a Private company.

  • What is Arch Oncology’s current revenue?

    The current revenue for Arch Oncology is .

  • How much funding has Arch Oncology raised over time?

    Arch Oncology has raised $226M.

  • Who are Arch Oncology’s competitors?

    Linnaeus Therapeutics and IgGenix are competitors of Arch Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »